IMR Press / EJGO / Volume 33 / Issue 3 / pii/1631086569188-17959493

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers
Show Less
1 Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama
2 Department of Obstetrics and Gynecology, Nara Prefectural Nara Hospital, Nara
3 Department of Obstetrics and Gynecology, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama (Japan)
Eur. J. Gynaecol. Oncol. 2012, 33(3), 269–273;
Published: 10 June 2012
Abstract

The normal serum CA125 half-life and distribution of the normal serum nadir CA125 value in patients with epithelial ovarian carcinoma (EOC) have not been determined yet. Among patients with EOC, 41 patients met the inclusion criteria of the present study: the patients that underwent complete cytoreductive surgery and six cycles of platinum-containing chemotherapy, and who had no recurrent disease more than five years. Serum CA125 half-life (T1/2) during primary surgery and primary chemotherapy was calculated and serum nadir CA125 level was evaluated by logarithmic-transformed serum CA125. Median value of nadir CA125 was 7 U/mL (range 3-20 U/mL), and the mean ln (serum nadir CA125) was 1.96 ± 0.45. Mean T1/2 was 10.4 days in all patients, and T1/2 value was associated with the preoperative serum levels of CA125. Predicted slope of CA125 regression curve was also influenced by the preoperative CA125 value. The present study provides fundamental information with regard to normal half-life time and normal nadir of CA125 in EOC patients.
Keywords
Ovarian cancer
CA125
Tumor marker
Half-life
Nadir
Share
Back to top